Keralam's SMA Medicine Dispute: Affordability, Evidence and Patient Trust

The condition affects the nerve–muscle connection

Motor neurons are nerve cells that carry instructions controlling muscle movement. SMA damages these cells in the spinal cord and lower brain, weakening the signals reaching muscles. Atrophy means wasting away, which helps explain the condition's name. The effects extend beyond difficulty walking or lifting the arms. Weakness can also affect the muscles involved in swallowing and breathing. Medical assessment therefore concerns several essential functions, rather than visible mobility alone.

In the common form of SMA, changes affecting the survival motor neuron 1 (SMN1) gene reduce a protein needed by motor neurons. The protein is also called survival motor neuron, or SMN. A related gene, survival motor neuron 2 (SMN2), can provide some functional protein, although much of its output is a shorter form. Differences in SMN2 copy number can influence severity, but do not determine every individual's course.

This common form is usually inherited in an autosomal recessive pattern. Both copies of SMN1 are affected, while parents carrying one changed copy often have no symptoms. A family may therefore encounter SMA without a history of visibly affected parents. Genetic testing helps establish the diagnosis and distinguish it from other causes of weakness.

Presentation varies between patients

Traditional SMA types describe when symptoms begin and the level of motor function achieved. Some forms appear before birth or in early infancy; others emerge in childhood or adulthood. The categories overlap, and severity varies. They help describe the condition, but should not be treated as an unchanging prediction of one person's future, particularly when treatment alters the course.

What risdiplam is intended to change

The European Medicines Agency describes risdiplam as a medicine that helps SMN2 produce more full-length SMN protein. This aims to support motor-neuron function and alter disease progression. Roche markets it under the name Evrysdi. The Hindu's report identifies Natsmart as Natco Pharma's generic risdiplam product. Those names identify different products involving the same active medicine; they are not names for two unrelated approaches to treating SMA.

The European regulator's assessment found benefits for motor function in studies of Evrysdi, with effects differing between patient groups. In later-onset disease, it described the measured improvement as modest. These findings support a therapeutic role without establishing a complete cure or identical benefit for every patient. They also concern the assessed reference medicine. Evaluating a generic involves the separate regulatory question of how evidence connects that product with its reference.

The public programme addresses a continuing access problem

Keralam's health department places SMA treatment within its rare-disease care programme, Kerala United Against Rare Diseases (KARE), launched in 2024. Its account announced an extension of free risdiplam coverage from children up to 12 to patients up to 25. The revised criteria referred specifically to genetically confirmed Type 2 SMA. It also identified a ₹30 crore budget allocation. These are the government's stated programme provisions, rather than a guarantee that every person with any form of SMA qualifies.

An announced eligibility expansion and actual medicine delivery are different stages. The programme must identify eligible patients, secure supplies and provide expert follow-up over time. A budget allocation describes financial provision; it is not the same as expenditure already incurred or patients already treated. This distinction matters when assessing whether access has expanded. The practical measure is sustained treatment reaching the people covered by the scheme.

Generic equivalence is an evidence question

The World Health Organization's registration guidelines distinguish the active ingredient from the complete pharmaceutical product. The active ingredient produces the intended therapeutic effect; other ingredients help form and deliver the medicine. Bioequivalence concerns whether comparable products make the medicine available in the body at a comparable rate and extent. It provides a bridge to evidence already established for the reference product. The required evidence depends on the medicine and its formulation.

The WHO guidelines recognise circumstances in which a conventional equivalence study is unnecessary, including certain equivalent oral solutions and powders prepared into such solutions. Conditions apply to the active ingredient, concentration and other ingredients. A waiver therefore follows a defined scientific basis; it does not mean that all checks disappear. Equally, a general waiver provision does not independently establish that any particular bottle or product meets every applicable requirement.

The label concern needs its own explanation

The newspaper reported that bottles dispensed at Thiruvananthapuram's Sree Avittom Thirunal Hospital carried wording referring to physician samples and clinical trials. Authorities said samples had been sourced directly from the manufacturer because the government consignment was delayed. That was their account of the supply circumstances. The label raised a legitimate communication question, but did not by itself establish that children had been enrolled in an unauthorised trial. Procurement records, product authorisation and clear explanations remain relevant.

Lower prices and quality assurance must work together

WHO's pharmaceutical-pricing guidance supports using quality-assured generic medicines to improve access. It also emphasises transparent prices, competition and carefully designed procurement policies. The word quality-assured is central: a public programme's objective is reliable treatment reaching more people. A lower price can make that possible, while consistent standards and understandable information help sustain confidence. Presenting affordability and evidence as separate necessities makes the policy question clearer.

WHO also recommends checking and revising pricing policies as conditions change. For a long-term treatment programme, savings matter alongside supply continuity and the ability to support additional eligible patients. A simple comparison of two advertised bottle prices cannot establish the programme's final cost. Negotiated prices, assistance arrangements and actual purchasing terms can change what the health system pays. Transparent transaction information provides a firmer basis for assessing value.

Continuing care includes function, safety and communication

MedlinePlus describes supportive care alongside medicines, including rehabilitation, mobility aids, nutritional support and help with breathing when needed. These measures address different consequences of muscle weakness and can support independence. Treatment needs vary, so no single illustration or programme description replaces individual specialist assessment. The practical aim is to maintain health and function through a coordinated care plan, with the patient and family able to understand its purpose.

The Indian Pharmacopoeia Commission's pharmacovigilance guidance encourages reporting suspected adverse reactions and possible lack of effectiveness. Pharmacovigilance means monitoring medicine safety during use. A report is a reason for assessment, rather than automatic proof that the medicine caused an event. Collecting relevant information and following up concerns can turn individual experiences into useful evidence for clinicians and regulators.

The same guidance explains that case reports can generate safety signals but have limitations, including under-reporting and uncertain causation. This supports a balanced response to families' concerns: take reports seriously, investigate them and explain findings clearly. It does not support dismissing every complaint or treating every deterioration as proof of generic failure. Ongoing clinical review and transparent communication are part of responsible care after any procurement decision.

Conclusion

The Keralam dispute connects a serious inherited condition with the practical challenge of financing sustained treatment. Wider access depends on affordable medicines, justified regulatory decisions, reliable supplies and care that continues beyond dispensing. Clear answers about product evidence and labelling can help families assess those decisions. Trust is strengthened when authorities explain the basis of treatment, respond to concerns and show how patients' progress and safety are being followed.